

Therapeutic Pipeline

Oncology

| Target | Modality | Indication | Discovery | Lead | Optimisation | Pre-clinical | Phase I | Phase II | Drug Discovery Partner | Partner/Licensee |
|-------------|------------------|----------------------|-----------|------|--------------|--------------|---------|----------|------------------------|------------------|
| Undisclosed | mAb | Undisclosed | ● | ● | ● | ● | ● | | | ● |
| CMV | CTL Platform | Glioblastoma | ● | ● | ● | ● | ● | | | |
| EBV | CTL Platform | Head & Neck | ● | ● | ● | ● | ● | | | ● |
| Undisclosed | Undisclosed | Undisclosed | ● | ● | ● | ● | ○ | | | ● |
| EBV | TCR-T cell | Head & Neck | ● | ● | ● | ● | ○ | | | ● |
| Undisclosed | Undisclosed | Solid Tumours | ● | ● | ○ | | | | | ● |
| SETDB1 | Bicyclic Peptide | Solid Tumours | ● | ● | ○ | | | | | |
| Galectin-9 | mAb | Solid Tumours | ● | ● | | | | | ● | |
| G9a | Small Molecule | Solid Tumours | ● | ● | ○ | | | | ● | |
| PDL2 | Protein | Solid Tumours | ● | ○ | | | | | | |
| EphA3 | CAR-T | Solid Tumours | ● | ○ | | | | | | |
| HPV | TCR-T cell | Head & Neck/Cervical | ● | ○ | | | | | | |
| Undisclosed | bsAb | Undisclosed | ● | ○ | | | | | | ● |
| NKG7 | Cell Platform | Solid Tumours | ● | | | | | | | |
| DNAM-1 | Cell Platform | Solid Tumours | ● | | | | | | | |



Infectious Disease and Transplant

| Target | Modality | Indication | Discovery | Lead | Optimisation | Pre-clinical | Phase I | Phase II | Drug Discovery Partner | Partner/ Licensee |
|--------------|------------------|---|-----------|------|--------------|--------------|---------|----------|------------------------|-------------------|
| CMV | CTL Platform | CMV Reactivation in Solid Organ Transplants | ● | ● | ● | ● | ● | | | |
| COVID-19 | CTL Platform | COVID-19 | ● | ● | ● | ● | ○ | | | |
| JCPyV | CTL Platform | Multifocal Leukoencephalopathy | ● | ● | ● | ● | | | ● | |
| BKPyV | CTL Platform | Undisclosed | ● | ● | ● | ● | | | ● | |
| CMV | Vaccine | CMV Infection | ● | ● | ● | | | | | |
| ACE2 | Bicyclic Peptide | COVID-19 | ● | ● | ● | | | | | |
| gp350 | mAb | EBV Associated PTLD | ● | ● | ○ | | | | | |
| Dengue Virus | Subviral RNA | Dengue Fever | ● | ○ | | | | | | |
| COVID-19 | TCR-T cell | COVID-19 | ● | | | | | | | |



Autoimmune, Neurology and Fibrosis

| Target | Modality | Indication | Discovery | Lead | Optimisation | Pre-clinical | Phase I | Phase II | Drug Discovery Partner | Partner/Licensee |
|-------------|----------------|---------------------------|-----------|------|--------------|--------------|---------|----------|------------------------|------------------|
| EBV | CTL Platform | Multiple Sclerosis | ● | ● | ● | ● | ● | ○ | | ● |
| Undisclosed | Peptide | Allergy/Asthma | ● | ● | | | | | | |
| Undisclosed | mAb | Autoimmune | ● | ○ | | | | | | ● |
| Undisclosed | miRNA | Liver Fibrosis | ● | ○ | | | | | | |
| TACI | mAb | Lupus Erythematosus | ● | | | | | | | |
| Undisclosed | mAb | Autoimmune | ● | | | | | | | ● |
| Undisclosed | Small Molecule | Cytokine Release Syndrome | ○ | | | | | | ● | |



Diagnostic Pipeline

Diagnostics

| Biomarker | Platform | Diagnostic method | Discovery | Proof of concept | Validation | Pre-clinical | Phase I | Phase II | Diagnostic Discovery Partner | Partner/Licensee |
|--------------------------------------|---|---|-----------|------------------|------------|--------------|---------|----------|------------------------------|------------------|
| Pan Cancer, exosome diagnostic | Examination of exosome markers | Exosome isolation then ELISA. Liquid biopsy | ● | ● | ● | | | | | |
| EAC Biomarkers | Circulating protein markers | Proteomics. Liquid biopsy | ● | ● | ● | ○ | | | | ● |
| PDL-1, post-translation modification | Predicting responsiveness to Immunotherapy | Flow cytometry or digital imaging platforms. Liquid or tissue biopsies. | ● | ● | ● | ● | ● | | | |
| miRNA Melanoma panel | Melanoma diagnosis and treatment response | Panel of 7 miRNAs for both liquid and tissue biopsies. Custom Taqman assay amplification plus Fluidigm PCR. | ● | ● | ○ | | | | | |
| EOMES diagnostic | Track T cell responsiveness to immunotherapy and acute/chronic viral infection (eg long Covid). | Liquid Biopsy, Tissue Biopsy, IFA multiplex. ASI Multiplex instrument | ● | ● | ○ | | | | | |

